GlassScriptPhysician profile
Ruth C Cholhan
NPI 1447291653
$7,337.28
in general payments reported to CMS, 2019-2025
30 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $336 · 2021: $742 · 2022: $955 · 2023: $769 · 2024: $1,916 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,064 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,063.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,385.94 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Abbvie INC. | $1,073.98 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $729.13 | 2019-2025 | Tremfya |
| Ucb, INC. | $657.55 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $524.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $515.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $361.83 | 2021-2025 | |
| Lilly USA, LLC | $311.77 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $266.77 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $224.05 | 2019-2025 | Orencia |
| Medtronic, INC. | $206.58 | 2024 | Corevalve Evolut R |
| Organon LLC | $174.80 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $117.55 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Genzyme Corporation | $106.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $104.52 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $99.29 | 2019 | |
| Radius Health, INC. | $82.83 | 2024-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $80.06 | 2023-2025 | Idacio |
| Mallinckrodt Enterprises LLC | $71.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.82 | 2023-2025 | Cyltezo, Spevigo |
| Celgene Corporation | $33.64 | 2019 | |
| Octapharma USA, INC. | $32.26 | 2022-2025 | Octagam Immune Globulin (Human) |
| Medexus Pharma, INC. | $23.98 | 2019 | |
| Biocon Biologics INC | $20.16 | 2024 | Hulio |
| Invivyd INC | $18.75 | 2025 | Pemgarda |
| Teva Pharmaceuticals USA, INC. | $15.70 | 2021 | |
| Kyowa Kirin, INC. | $15.59 | 2023 | |
| Mylan Institutional INC. | $13.34 | 2023 | Fulphila |
| Mallinckrodt Hospital Products INC. | $12.35 | 2020 | |
| Hikma Pharmaceuticals USA | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Cholhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.